

Greater Midlands Cancer Network

Meeting: Shropshire and Telford and Wrekin Joint Overview and Scrutiny

Committee.

Subject: Update on the Gynaecological Cancer Audit

Report by: Damian Murphy Medical Director GMCN

Date: 6th March 2012

The GMCN has implemented the changes necessary following the implementation of the Gynaecological Cancer NICE Improving Outcomes Guidance.

It is good practice that ethical committee approval be sought for this type of audit. Ethical approval ensures robust peer review of the audit process and of the questionnaire to be used. Full ethical approval has been obtained and we are now in a position to carry out the audit process.

The questionnaire that was submitted to the University Ethics Committee is attached to this report and demonstrates the breadth and depth of the study to be carried out.

Using the Somerset data system we are able to see numbers of patients transferred and below is a summary of Gynaecological Cancer first seen at SaTH.

This information covers a period from April 2011 to December 2011

		Treating Trust				
Tumour Type	Expected	SaTH	UHN	NX	Total	%
	Transfer rate		S			Transferre
						d
Vulval	100%	6	2	0	8	25%
Cervix	90%	3	0	3	6	50%
Endometrial	20%	30	2	4	36	17%
Ovarian	75%	12	0	5	17	29%
Other	50%	0	1	0	1	100%
Total		51	5	12	68	

As can be seen the numbers transferred are extremely small, seventeen out of sixty eight patients have been transferred over the nine month period. We expect these numbers to

increase and intend to audit prospectively using the attached questionnaire as well as the Somerset database. To date we have not had any difficulties reported to us by the teams involved or any patient complaints regarding this service.

The audit will commence shortly and clearly, given the numbers transferring, will take a little time to complete. We will ensure you are sent a copy of the final report and are happy to answer any questions in the meantime.